PMID- 17309668
OWN - NLM
STAT- MEDLINE
DCOM- 20071129
LR  - 20181030
IS  - 1048-891X (Print)
IS  - 1048-891X (Linking)
VI  - 17
IP  - 4
DP  - 2007 Jul-Aug
TI  - The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial 
      ovarian cancer.
PG  - 798-807
AB  - Both cyclooxygenase 2 (COX2) and human epidermal growth factor receptor 2 (HER2, 
      also called c-erbB-2) overexpression have been related to a worse prognosis in 
      epithelial ovarian cancer (EOC), but the data are conflicting and the percentage 
      of tumors with overexpression varies widely in different studies. The aim of this 
      study was to investigate the potential prognostic value of COX2 and HER2 
      expression in EOC. A further purpose was to investigate a possible coexpression 
      of the two markers, and finally, to elucidate the agreement between fluorescence 
      in situ hybridization (FISH) and immunohistochemistry (IHC) for evaluation of the 
      HER2 status in EOC. Immunostaining was performed for COX2/HER2 together with FISH 
      analysis for HER2 gene amplification in 160 patients with EOC, FIGO stages 
      IIB-IV. Follow-up was more than 10 years. COX2 overexpression was found in 20.0% 
      of the tumors. With HER2 staining, 64.4% were scored as 0, 24.4% as 1+, 6.9% as 
      2+, and 4.4% as 3+. Median survival time for COX2-negative tumors was 21.6 versus 
      36 months for COX2-positive tumors. The longer survival for COX2 positive was 
      significant by both univariate analysis (P= 0.015) and multivariate analysis (P= 
      0.025). Positive immunostaining for HER2 was associated with poor overall 
      survival (P= 0.03). Agreement between IHC and FISH was seen in all cases (P < 
      0.0000001). With long-term observation, patients with negative COX2 expression 
      had significantly shorter survival compared to patients with COX2-positive 
      tumors. Positive HER2 expression also notified a grave prognosis, but the low 
      rate of overexpression reduces its potential clinical application.
FAU - Steffensen, K D
AU  - Steffensen KD
AD  - Department of Oncology, Vejle Hospital, Vejle, Denmark. 
      Karina.Dahl.Steffensen@vgs.regionsyddanmark.dk
FAU - Waldstrom, M
AU  - Waldstrom M
FAU - Jeppesen, U
AU  - Jeppesen U
FAU - Jakobsen, E
AU  - Jakobsen E
FAU - Brandslund, I
AU  - Brandslund I
FAU - Jakobsen, A
AU  - Jakobsen A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070216
PL  - England
TA  - Int J Gynecol Cancer
JT  - International journal of gynecological cancer : official journal of the 
      International Gynecological Cancer Society
JID - 9111626
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cyclooxygenase 2/*biosynthesis/genetics/metabolism
MH  - Epithelial Cells/pathology
MH  - Female
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Ovarian Neoplasms/*enzymology/genetics/pathology
MH  - Prognosis
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Survival Analysis
EDAT- 2007/02/21 09:00
MHDA- 2007/12/06 09:00
CRDT- 2007/02/21 09:00
PHST- 2007/02/21 09:00 [pubmed]
PHST- 2007/12/06 09:00 [medline]
PHST- 2007/02/21 09:00 [entrez]
AID - IJG855 [pii]
AID - 10.1111/j.1525-1438.2006.00855.x [doi]
PST - ppublish
SO  - Int J Gynecol Cancer. 2007 Jul-Aug;17(4):798-807. doi: 
      10.1111/j.1525-1438.2006.00855.x. Epub 2007 Feb 16.